Navigation Links
Ardelyx Reports Second Quarter 2014 Financial Results
Date:8/7/2014

FREMONT, Calif., Aug. 7, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced financial results for the second quarter ended June 30, 2014.

Summary of First Half 2014 Accomplishments

  • Ardelyx raised net proceeds of approximately $61.2 million in an initial public offering of its common stock, and on June 19, 2014, its shares began trading on the NASDAQ Global Market(SM) under the symbol "ARDX".
  • The Company received a milestone payment under its collaboration agreement with AstraZeneca of $25.0 million in May 2014 for the initiation of a Phase 2b clinical trial evaluating tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, in patients with end-stage renal disease on hemodialysis (ESRD-HD).
  • Tenapanor, which has been shown in clinical trials to reduce the intestinal absorption of both dietary sodium and phosphorus, is currently being evaluated by Ardelyx and AstraZeneca in three separate Phase 2 clinical trials involving patients with constipation-predominant irritable bowel syndrome (IBS-C), end-stage renal disease (ESRD), and chronic kidney disease (CKD). The data from these trials are expected as follows:
  • Phase 2b results evaluating tenapanor to treat IBS-C in 4Q2014
  • Phase 2b results evaluating tenapanor to treat hyperphosphatemia in ESRD patients in 1H2015
  • Phase 2a results evaluating tenapanor to treat CKD patients with type 2 diabetes mellitus and albuminuria in 2H2015
  • In Ardelyx's collaboration with AstraZeneca, a total of 12 clinical trials of tenapanor have been completed or are ongoing, enrolling over 1,200 subjects, including over 830 subjects who have been administered tenapanor to date.
  • In February 2014, Ardelyx licensed its novel Na
    '/>"/>

  • SOURCE Ardelyx, Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
    2. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
    3. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
    4. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
    5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
    6. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
    7. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
    8. Luminex Corporation Reports First Quarter 2012 Results
    9. Hospira Reports First-Quarter 2012 Results
    10. Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
    11. The Female Health Company Reports Second Quarter Operating Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... MOUNTAIN VIEW, Calif. , Oct. 22, ... 11:00 a.m. EDTLOCATION: Online, complimentary registration available ... Group Team Leader Archana Vidyasekar and Visionary ... VargheseBrain-controlled computers, WiFi-like wireless electricity, self-assembling materials, ... top ten technologies which will transform our ...
    (Date:10/22/2014)... -- Recently published clinical studies of Stretta for gastroesophageal reflux ... evidence. This data has led to significantly expanded insurance ... sufferers of refractory GERD. The substantial ... as a safe and effective GERD treatment has driven ... nearly 50 million Americans. The new clinical studies include; ...
    (Date:10/20/2014)... VIEW, California , 20 de octubre de ... líder en el campo de la pulmonología intervencional, ... su Estudio RENEW, casi 3 meses antes de ... fundamental de exención de dispositivo de investigación (IDE) ... Medicamentos) para el sistema de espiral de reducción ...
    Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
    ... Mitsubishi Chemical Medience Corporation announced today that the ... 510(k) premarketing notification clearance to the PATHFAST® cTnI-II ... for its sale in the United States. The ... PATHFAST analysis system, a unique, self-contained, bench-top chemi-luminescence ...
    ... Reportlinker.com announces that a new market research ... Distributor Analysis of the Pharmaceutical ... http://www.reportlinker.com/p0552921/Distributor-Analysis-of-the-Pharmaceutical-Industry-in-Key-SADC-Countries.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu ... to present an overview of the pharmaceutical ...
    Cached Medicine Technology:Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 2Mitsubishi Chemical Medience Corporation Receives 510(k) Clearance for PATHFAST® cTnI-II (cardiac Troponin I) Test in U.S. 3Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 2Reportlinker Adds Distributor Analysis of the Pharmaceutical Industry in Key SADC Countries 3
    (Date:10/22/2014)... (PRWEB) October 22, 2014 The ... , which is dedicated to distribute health information ... healthcare delivery worldwide announced the development of six ... patients expect when receiving healthcare. These are an ... patient-centered care: “providing care that is respectful of ...
    (Date:10/22/2014)... 2014 With the Affordable Care Act (ACA) ... the American Institutes for Research (AIR) finds that three out ... health insurance, but 42 percent say they are not likely ... signing up for coverage. , The AIR survey found wide ... able to calculate correctly how much they owe for a ...
    (Date:10/22/2014)... October 22, 2014 Best Cheap Hosting ... the world. The site has recently announced that iPower ... supplier for people from around the world. , “iPower ... operation today and is providing various kinds of useful ... company insists on offering excellent customer service and a ...
    (Date:10/22/2014)... 22, 2014 Losing Weight Your Body’s Way ... staring you in the face, it certainly can be difficult ... your body an extra favor by doing it the healthy ... diets. Instead, listen to your body, exercise regularly, and choose ... essential to losing weight; you need to exercise more and ...
    (Date:10/22/2014)... Lintelus, Inc., an event software provider, ... Sales, will be speaking on the subject of “Event ... October 28, at the Holiday Inn in New York ... well as a Tech Demo at 12:45pm, to educate ... more engaging event experience. , The Annual Meetings Technology ...
    Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2
    ... Strike Anyone, Anywhere; Urges Americans to Work With CPF to ... (PF) claims a life every 13 minutes in the U.S., ... cancer; yet most Americans have never heard of the disease ... Coalition for Pulmonary Fibrosis (CPF) today launched a new public ...
    ... techniques, the accuracy of preoperative rectal cancer staging has ... rectal cancer patients has become a very important aim ... published on March 14, 2009 in the World ... 5-year survival after local excision of rectal cancer, and ...
    ... of Nicotine and Tobacco Research Analyzes Trends, Impact of ... majority of research conducted about tobacco use has been ... The March 2009 issue of Nicotine and ... intermittent smoking. Several of the nation,s preeminent public health ...
    ... works for some people might be dangerous for others, ... confirmed previously reported genetic factors that may help doctors ... thinner warfarin to people at high risk of cardiovascular ... Administration estimates, about 2 million Americans use the anticoagulant ...
    ... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... market withdrawal/recall of thirty-nine (39) lots of the ADHD ... this action are listed below). Shire is taking ... their release liner removal specification, and as a result, ...
    ... campaign which will reduce mortality in patients with acute ... which includes the ESC Working Group on Acute Cardiac ... (EAPCI). "Stent 4 Life" is a project designed to ... coronary interventions (PCI, with balloon angioplasty and stent) in ...
    Cached Medicine News:Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 2Health News:CPF Launches National PSA to Educate Public on Pulmonary Fibrosis 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 2Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 3Health News:New Analysis: Light and Intermittent Smokers Overlooked in Traditional Tobacco Research 4Health News:Genetics Should Decide Warfarin Dose, Study Reiterates 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 2Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 3Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 4Health News:Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA(R) (methylphenidate transdermal system) patches announced 5Health News:'Stent 4 Life': A campaign is launched to increase the use of primary PCI in acute coronary patients 2
    ... OptiMumm™ smoke evacuator is ... complete smoke evacuation system ... AccuVac™ smoke evacuation attachment, ... and either the Force ...
    Turnstile casting stand for easy and safe casting. The compact system sets up quickly and stores conveniently, and the non-stick coating prevents fiberglass or plaster from adhering to surface....
    Bone cement with Gentamicin 2.5%....
    ... Techno-Aide provides the highest level ... highest quality lead protective eyewear. ... + tolerance allowed. Mfg supervised by ... All lens meet or exceed standards ...
    Medicine Products: